JENNY FARRIS: Open Payments
NPI 1417662925 · TISHOMINGO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$657 in 46 payments from 10 companies in 2025. Trend: 2023 $28 · 2024 $198 · 2025 $657
Food & beverage: $657
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $282 |
| Phathom Pharmaceuticals, Inc. | 1 | $105 |
| Novo Nordisk Inc | 3 | $49 |
| Amgen Inc. | 3 | $48 |
| IBSA Pharma Inc. | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
Products named: VRAYLAR, VOQUEZNA, UBRELVY, QULIPTA, Wegovy, OTEZLA, Tirosint, FARXIGA.
Industry payments across MS — which companies pay providers there.
